https://clinicaltrials.gov/study/NCT06699836?...y-overview Ps. I guess they limited participants for now. Maybe more can be allowed later. A lot of patients are not close to qualifying
Participants entering this cohort will receive leronlimab 700 mg subcutaneously once weekly in combination with pembrolizumab 200 mg administered intravenously every 3 weeks. Approximately 12 participants may be enrolled in this cohort and may receive treatment for up to 48 weeks.